NSCLC Coverage From Every Angle
Advertisement
Advertisement

Martin Reck, MD, PhD, on Selecting Immunotherapy

Posted: Tuesday, November 14, 2017

Although nivolumab, for instance, may be prescribed for patients with low or no PD-L1 expression, how likely are you to select immunotherapy for such patients? Ā 



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.